We are live on ! Find out more
MBRX icon

Moleculin Biotech
MBRX

20 hedge funds and large institutions have $348K invested in Moleculin Biotech in 2026 Q1 according to their latest regulatory filings, with 7 funds opening new positions, 4 increasing their positions, 2 reducing their positions, and 3 closing their positions.

New
Increased
Maintained
Reduced
Closed

133% more first-time investments, than exits

New positions opened: 7 | Existing positions closed: 3

100% more repeat investments, than reductions

Existing positions increased: 4 | Existing positions reduced: 2

18% more funds holding

Funds holding: 17 → 20 (+3)

10% more capital invested

Capital invested by funds: $315K → $348K (+$32.7K)

0.24% less ownership

Funds ownership: 3.09% → 2.85% (-0.24%)

Holders
20
Holders Change
+3
Holders Change %
+17.65%
% of All Funds
0.25%
Holding in Top 10
1
Holding in Top 10 Change
+1
Holding in Top 10 Change %
% of All Funds
0.01%
New
7
Increased
4
Reduced
2
Closed
3
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
SM
Sabby Management
Florida
+$248K
2
Geode Capital Management
Geode Capital Management
Massachusetts
+$56.9K
3
HF
HRT Financial
New York
+$45.5K
4
Rockefeller Capital Management
Rockefeller Capital Management
New York
+$13.9K
5
TRCT
Tower Research Capital (TRC)
New York
+$1.46K

Top Sellers

Rank Fund Capital Flow
1
Citadel Advisors
Citadel Advisors
Florida
-$110K
2
Jane Street
Jane Street
New York
-$74.6K
3
UBS Group
UBS Group
Switzerland
-$8.12K
4
Bank of America
Bank of America
North Carolina
-$119
5
BlackRock
BlackRock
New York
-$13
Name Holding Trade Value Shares
Change 		Change in
Stake
SM
1
Sabby Management
Florida
$172K +$248K +75,021 New
Geode Capital Management
2
Geode Capital Management
Massachusetts
$74K +$56.9K +17,191 +114%
VCM
3
Vanguard Capital Management
Pennsylvania
$31.8K +$45.9K +13,869 New
HF
4
HRT Financial
New York
$31K +$45.5K +13,739 New
VFT
5
Vanguard Fiduciary Trust
Pennsylvania
$13.9K +$20.1K +6,072 New
Rockefeller Capital Management
6
Rockefeller Capital Management
New York
$10.1K +$13.9K +4,203 +1,928%
UBS Group
7
UBS Group
Switzerland
$7.81K -$8.12K -2,454 -42%
TRCT
8
Tower Research Capital (TRC)
New York
$4.2K +$1.46K +442 +32%
BlackRock
9
BlackRock
New York
$1.12K -$13 -4 -0.8%
EI
10
EFG International
$994 – – –
PWPS
11
Pinnacle Wealth Planning Services
Ohio
$643 – – –
NFSG
12
Newbridge Financial Services Group
Florida
$261 – – –
SS
13
SBI Securities
Japan
$98 +$46 +14 +48%
Morgan Stanley
14
Morgan Stanley
New York
$83 – – –
VGA
15
Vanguard Global Advisers
Pennsylvania
$55 +$79 +24 New
Fidelity Investments
16
Fidelity Investments
Massachusetts
$7 +$10 +3 New
DB
17
Danske Bank
Denmark
$5 – – –
CIAM
18
Caitong International Asset Management
Hong Kong
$5 +$7 +2 New
CFO
19
CVA Family Office
Colorado
$2 – – –
Osaic Holdings
20
Osaic Holdings
Arizona
$2 – – –
Citadel Advisors
21
Citadel Advisors
Florida
– -$110K -33,085 Closed
Jane Street
22
Jane Street
New York
– -$74.6K -22,550 Closed
Bank of America
23
Bank of America
North Carolina
– -$119 -36 Closed

MBRX Hedge Fund Activity: Q1 2026 in Review

20 of the 8,134 institutional investors tracked by Wall St. Rank reported a position in Moleculin Biotech (MBRX) for Q1 2026, worth a combined $348K — up 10% from $315K a quarter earlier.

Buyers outnumbered sellers: 7 funds opened new MBRX positions and 3 closed out — a net gain of 4 holders — while 4 added to existing stakes and 2 trimmed.

The largest buyer was Sabby Management, opening a new position worth an estimated $248K. The largest seller was Citadel Advisors, exiting entirely with an estimated $110K sold.

  • 20 institutional investors held Moleculin Biotech (MBRX) as of Q1 2026, up from 17 in Q4 2025.
  • Funds reported $348K of Moleculin Biotech stock for Q1 2026, up 10% quarter-over-quarter.
  • 7 funds opened new Moleculin Biotech positions in Q1 2026 and 3 closed out, a net change of +4 holders.
  • The largest Moleculin Biotech buyer in Q1 2026 was Sabby Management, an estimated $248K added.
  • The largest Moleculin Biotech seller in Q1 2026 was Citadel Advisors, an estimated $110K sold.

Based on aggregated 13F filings for Q1 2026.